Amyotrophic Lateral Sclerosis (ALS)

BrainStorm Hopes to Bring ALS Stem Cell Trial to US

Biotechnology company BrainStorm Cell Therapeutics has announced plans to collaborate with two American institutions to test its experimental stem cell technology in people with amyotrophic lateral sclerosis (ALS) in the United States. The institutions are Massachusetts General Hospital in Boston and the University of Massachusetts Medical School in Worcester, Mass.

Amyotrophic Lateral Sclerosis Care Guidelines

 

The American Academy of Neurology (AAN) released its new guidelines on patient care in amyotrophic lateral sclerosis (ALS) on Oct. 13, 2009. Several MDA-affiliated physicians were involved in their development.

Last Updated: 
Thu, 10/01/2009 - 13:17

MDA ALS Caregiver's Guide

Download a printable PDF of the entire guidebook PDF Document


The Journey

If you’re reading this guide, it’s probably because someone you care about deeply has ALS.

Last Updated: 
Fri, 03/01/2013 - 16:21

ALS Registry Touts Revamped Website, New Surveys

In hopes of collecting as much information as possible, the National ALS Registry, which opened in October 2010, already is expanding its reach.

Registry officials have made the enrollment process easier and are adding surveys about potential risk factors to the registry’s website.

Everyday Life with ALS: A Practical Guide

Download a printable PDF of the entire guidebook PDF Document


Introduction

Receiving a diagnosis of amyotrophic lateral sclerosis (ALS) will unquestionably alter your life in almost every aspect.

Last Updated: 
Sat, 03/13/2010 - 13:34

Research Briefs: FA, MG, MM, MMD1, gene therapy

Edison drugs target FA, mitochondrial diseases

Second Phase 2 Trial of CK-2017357 Under Way

San Francisco biotechnology company Cytokinetics announced June 21, 2011, that it has opened enrollment for a new clinical trial of CK-2017357 at three different dosage levels in people with ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).

ALS Research Briefs: Ataxin 2 Gene

In a 2010 study, scientists working in the United States and Germany found that small polyglutamine ("polyQ")expansions of DNA in the ataxin 2gene significantly increase the risk for developing ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).

Expansions of DNA coding for glutamine in the ataxin 2 gene lead to production of expanded ataxin 2 proteins, containing extra strings of glutamine amino acid molecules.

Pages